본문 바로가기

technology

SuperNK®

SuperNK is a patented immunotherapy
With a culturing technology that mass produces 99% pure NK cells
with superior killing ability.

(PCT patents registered/pending in the U.S., China, Korea, and more.)

NK Cell Culture Technology of SuperNK®

Existing NK cell culture technologies mainly use highly concentrated cytokines, which only increase the number of NK cells (proliferation). SuperNK’s novel cell culture technology uses cytotoxicity enhancing agents and proliferating agents that the result is both highly cytotoxic and a large number of NK cells.
SuperNK® has unique patented NK cell culture technology.

Existing NK cell culture technology

Treatment with cytokine  - Simple culture method (Simple proliferation of NK cells)

Novel NK cell culture technology

Treatment with cytokine and cell killing activity enhancer - Novel complex culture method (Proliferation of highly active (cytotoxic) NK cells)

Comparison of NK cells’ purity and killing ability between SuperNK vs. others

SuperNK’s patented culture technology produces 99% pure NK cells. SuperNK’s patented culture technology shows 90% killing ability when reacted with cancer cells.

SuperNK®, the novel potential immunotherapy that overcomes the limitations of the existing NK cell therapies

Limitation of existing NK cell therapies Superiority of SuperNK®
Generally display decreased killing ability
Killing ability improved
SuperNK cells display superior cell killing ability at lower ratios.
Lower NK cell purity containing a large portion of other immune cells
High purity of NK cells
SuperNK contains NK cells with a purity of 99%.
Difficult in vitro mass production
Mass production available
Through SNK’s patented culturing technology, NK cells proliferate from 5,000 to 19 billion folds.
Ineffective treatment due to inhibition of Immune function in cancer patients
Better survival and activity in cancer patients.
Produces enough cytotoxic cells for increased survival/activity to overcome cancer patients’ immune inhibitory environment.

Move to Top